Indications of lisinopril
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Indications of Lisinopril
Hypertension Management
Lisinopril is widely recognized for its efficacy in managing hypertension. It functions as an angiotensin-converting enzyme (ACE) inhibitor, which helps to reduce blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to a decrease in plasma angiotensin II and aldosterone levels, and an increase in plasma renin activity, resulting in a smooth and gradual reduction in blood pressure without significantly affecting heart rate or cardiovascular reflexes. Lisinopril has been shown to produce greater reductions in both systolic and diastolic blood pressure compared to hydrochlorothiazide (HCTZ) and is comparable to nifedipine in its efficacy. Additionally, it is effective in obese hypertensive patients, showing significant blood pressure reductions and a favorable safety profile compared to HCTZ.
Congestive Heart Failure Treatment
Lisinopril is also indicated for the treatment of congestive heart failure (CHF). It has been demonstrated to increase exercise duration, improve left ventricular ejection fraction, and enhance overall functional capacity in patients with CHF who remain symptomatic despite treatment with digoxin and diuretics . In elderly patients, lisinopril has shown similar or superior efficacy compared to captopril, another ACE inhibitor, in improving exercise tolerance and left ventricular function . The addition of lisinopril to standard CHF therapy has been associated with significant improvements in quality of life and functional capacity.
Acute Myocardial Infarction Management
Lisinopril has proven benefits in the early management of acute myocardial infarction (AMI). Administered within 24 hours of symptom onset, it has been shown to reduce mortality and cardiovascular morbidity by attenuating the detrimental effects of left ventricular remodeling . The GISSI-3 trial demonstrated that lisinopril, given for six weeks post-AMI, significantly reduced the risk of mortality and severe left ventricular dysfunction . These benefits were observed across various patient subgroups, including high-risk populations such as the elderly and those with diabetes mellitus.
Renal Protection in Chronic Kidney Disease
Lisinopril is beneficial in slowing the progression of chronic kidney disease (CKD), particularly in patients with proteinuric non-diabetic nephropathies. It has been shown to significantly reduce the decline in renal function compared to other antihypertensive agents, suggesting a specific renoprotective effect beyond blood pressure control. This makes lisinopril a valuable option for patients with mild proteinuria and chronic renal insufficiency.
Pulmonary Hypertension
Lisinopril has also been studied for its effects on hypoxic pulmonary vasoconstriction (HPV). It significantly attenuates the pulmonary pressor response to hypoxemia without affecting baseline pulmonary artery pressure or total pulmonary vascular resistance, indicating its potential as an adjunctive treatment in hypoxemic pulmonary hypertension.
Conclusion
Lisinopril is a versatile ACE inhibitor with multiple indications, including hypertension, congestive heart failure, acute myocardial infarction, chronic kidney disease, and pulmonary hypertension. Its efficacy in reducing blood pressure, improving cardiac function, and providing renal protection makes it a valuable therapeutic option across various cardiovascular and renal conditions.
Sources and full results
Most relevant research papers on this topic